Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 2021

View Archived Issues

IL-27 drives metabolic programs and its targeting aids in the treatment of obesity

FBXO22 sensitizes tumor cells to DNA damage by PD-L1 degrading

Novel syngeneic bladder cancer model using organoid line with specific gene deletions

Ube Industries patents integrin alphav antagonists

Suzhou Zelgen Biosciences synthesizes new GTPase KRAS mutant inhibitors

Glixogen Therapeutics identifies GLI1 inhibitors

Jiangsu Chia Tai Tianqing Pharmaceutical Group presents SOS1 inhibitors

Shanghai Zheye Biotechnology divulges new SGLT-1 inhibitors

RAGE-229 inhibits RAGE-DIAPH1 binding and lessens diabetic complications in mice

[68Ga]SP-94 shows excellent uptake in GRP78-positive HCC tumors

GP73 analysis aids in the diagnosis of NASH and staging of hepatic fibrosis

Targeting TWEAK shows potential as alternative therapeutic strategy for psoriasis

Oragenics reports on SARS-CoV-2 vaccine formulations in hamster challenge study

MALT1 mutant mice reveal role of E3 ligase TRAF6 in peripheral immune tolerance

Stepwise engineered IL-37-Fc-fusion protein shows improved therapeutic likeness

Small molecule allows targeted degradation of repeat expansion in vitro and in vivo in ALS models

Chimeric obtains option to license CORE-NK platform from Case Western Reserve University

DREADD approach calms neuropsychiatric dread circuits in primates

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...